Zoldonat Injection Market Global Report 2026

The zoldonat injection market size has grown strongly in recent years. It will grow from $1.73 billion in 2025 to $1.84 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to the rising prevalence of osteoporosis and other bone-related conditions, increasing occurrence of bone complications associated with cancer, growing aging populations requiring effective bone health management, rising utilization of intravenous bisphosphonate treatments, expanding healthcare infrastructure supporting specialized treatment services.

The zoldonat injection market size is expected to see strong growth in the next few years. It will grow to $2.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing demand for effective treatments for bone loss management, growing adoption of generic zoledronate injection products, rising requirements for supportive oncology care, expanding access to specialized healthcare services, and increasing emphasis on advanced injectable drug delivery technologies. Major trends in the forecast period include growing development of advanced bisphosphonate formulations aimed at enhancing therapeutic outcomes, increasing focus on targeted therapies for managing bone metabolism, rising adoption of hospital-based intravenous treatment approaches for osteoporosis, expanding availability of affordable generic zoledronate injection products, and increasing emphasis on improving treatment adherence and accessibility.

The rising prevalence of osteoporosis is expected to propel the growth of the zoldonat injection market going forward. Osteoporosis is a bone disease characterized by decreased bone density and deterioration of bone structure, which increases the risk of fractures, particularly among the aging population. The prevalence of osteoporosis is increasing due to aging populations, as bone density naturally declines with age, resulting in weaker bones and a greater likelihood of fractures, particularly among older adults. Zoldonat Injection, containing zoledronic acid, is used in the management of osteoporosis by helping reduce bone loss and improve bone mineral density, thereby supporting the treatment needs of patients with weakened bones. For instance, in July 2025, according to the Deakin University Health Transformation Lab, an Australia-based health research organization, by 2033, 7.7 million Australians aged 50 years and older are projected to have osteoporosis and osteopenia, representing a 23% increase from 2023. Therefore, the rising prevalence of osteoporosis is driving the growth of the zoldonat injection market.

The growth in healthcare expenditure is expected to propel the growth of the zoldonat injection market going forward. Healthcare expenditure refers to the total amount spent on healthcare goods and services, including hospital care, physician services, medications, medical devices, preventive care, health administration, and public health activities by governments, private organizations, and individuals. Healthcare expenditure is increasing due to the rising prevalence of chronic diseases, which require long-term treatment, continuous medical monitoring, and advanced therapies, resulting in higher healthcare costs for patients and healthcare systems. Healthcare expenditure supports access to zoldonat injection by facilitating essential treatment, improving patient management, reducing the burden of disease-related complications, and promoting the availability of advanced therapies that contribute to improved healthcare outcomes. For instance, in December 2025, according to the California Health Care Foundation, a US-based nonprofit philanthropy, health expenditure in 2023 reached $4.9 trillion, or $14,570 per person, and grew by 7.5%, up from a 4.6% increase in 2022. Therefore, the growth in healthcare expenditure is driving the growth of the zoldonat injection market.

Key companies operating in the zoldonat injection market are focusing on developing innovative products such as generic injectable bisphosphonate therapies to enhance treatment accessibility, improve medication availability, and support effective management of cancer-related bone complications. Generic injectable bisphosphonate therapies are cost-effective intravenous medications that contain bisphosphonate compounds designed to inhibit bone breakdown by reducing osteoclast activity, helping manage cancer-related bone complications, lower the risk of skeletal-related events, control high calcium levels in the blood, and improve access to essential treatments compared with branded alternatives. For example, in February 2025, Avenacy, a US-based specialty pharmaceutical company focused on critical injectable medications, launched Zoledronic Acid Injection, USP in the US market as a therapeutic generic equivalent to Zometa. The product is available as a 4 mg/5 mL single-dose vial (0.8 mg/mL) and is designed for intravenous administration in medically supervised settings. The injection is indicated for the treatment of hypercalcemia of malignancy and for patients with multiple myeloma and bone metastases from solid tumors in combination with standard antineoplastic therapy. The product features differentiated packaging and labeling designed to support accurate medication selection and improve patient safety. This launch highlights the growing trend toward expanding access to essential injectable oncology therapies through high-quality generic alternatives.

Major companies operating in the zoldonat injection market are Novartis AG, Sun Pharmaceutical Industries Limited, Cipla Limited, Dr. Reddy's Laboratories Limited, Intas Pharmaceuticals Limited, Hetero Labs Limited, Natco Pharma Limited.

North America was the dominant region in the zoldonat injection market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the zoldonat injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the zoldonat injection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.